Recent News

• 05.15.2026 - aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
• 05.13.2026 - aTyr Pharma to Participate in Upcoming Investor Conferences
• 05.11.2026 - aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
• 03.05.2026 - aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
• 02.20.2026 - aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 02.18.2026 - aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
• 02.03.2026 - aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis

Recent Filings

• 05.15.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.15.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.08.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.08.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.06.2026 - EX-99.1 EX-99.1
• 05.06.2026 - 8-K Current report
• 05.01.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 03.17.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]